The remarkably frequent use of EQ-5D in non-economic research.


Journal

The European journal of health economics : HEPAC : health economics in prevention and care
ISSN: 1618-7601
Titre abrégé: Eur J Health Econ
Pays: Germany
ID NLM: 101134867

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 26 01 2021
accepted: 11 11 2021
pubmed: 1 12 2021
medline: 26 7 2022
entrez: 30 11 2021
Statut: ppublish

Résumé

EQ-5D is an instrument which has been utilized for a variety of purposes, including in health-economic appraisals as an input into quality-adjusted life year (QALY) calculations. Indeed, it is the most-widely applied instrument for health-economic appraisal worldwide, and is recommended for use in QALY calculations by many national Health Technology Assessment (HTA) agencies. There is also a growing body of evidence for its usefulness in a variety of settings other than economic appraisals, but such use has not been well-documented. This study addresses this issue and documents how EQ-5D has been applied in both the non-economic and economic contexts. The PubMed database was searched using the terms 'EQ-5D', 'EQ-5D AND cost', and 'EQ-5D AND cost AND QALY' from 1 January 1980 to 31 December 2019. We concentrated on 2019 publications for more detailed analyses. All the data collected for 2019 were downloaded and collected in EndNote. For 2019 only, we classified economic and non-economic use based on the inclusion of 'cost'. We also checked by manual inspection whether the search terms were suitable in correctly identifying economic and non-economic use. Variants of the non-economic use of EQ-5D were classified as follows: (a) as a quality of life outcome measure; (b) as a tool for methodological research; (c) methodological issues of EQ-5D itself; (d) comparisons with other quality of life questionnaires; (e) mapping studies; (f) value sets; (g) alongside costs but no QALY calculated; and (h) other. The first publication found was from 1990. Up to and including 2019, 10,817 publications were identified, of which more than two in three did not contain any reference to costs or QALYs. In 2019, a total of 1409 manuscripts were identified, of which 239 were specifically for EQ-5D-5L.  Four hundred and seven (28.9%) included some form of 'costs' and 157 (11.1%) both 'costs' AND 'QALYs' terms. For EQ-5D-5L, the corresponding numbers were 104 (43.5%) and 29 (12.1%), respectively. After manually checking all the 1409 papers, three were duplicated records, which were omitted. In the remaining 1406 papers, only 40 (2.8%) contained the term 'cost', but not 'cost per QALY', and only 117 (8.3%) were identifiable as economic evaluations using the term 'cost per QALY'. Most non-economic use of EQ-5D was as a quality-of-life outcome measure (72.8%). Other applications were: as a tool for methodological research (6.7%); comparison studies (3.7%); EQ-5D methodological issues (3.5%); containing costs but not QALYs (2.8%); mapping (1.3%); value sets (0.4%); and other papers (0.4%). The majority of the studies retrieved, covering a wide variety of research areas, reported upon the non-economic use of EQ-5D. Despite being the most-used instrument worldwide for QALY calculations, economic appraisal accounted for only a small, but important, part of published use.

Identifiants

pubmed: 34846623
doi: 10.1007/s10198-021-01411-z
pii: 10.1007/s10198-021-01411-z
pmc: PMC9304056
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1007-1014

Informations de copyright

© 2021. The Author(s).

Références

J Dermatolog Treat. 2019 May;30(3):208-215
pubmed: 30102075
Actas Esp Psiquiatr. 2019 May;47(3):97-109
pubmed: 31233208
Expert Rev Pharmacoecon Outcomes Res. 2019 Jun;19(3):321-329
pubmed: 30221564
Med Care. 2007 Mar;45(3):259-63
pubmed: 17304084
Health Soc Care Community. 2019 Sep;27(5):1311-1320
pubmed: 31149764
Pharmacoeconomics. 2014 Apr;32(4):367-75
pubmed: 24477679
Clin Nutr. 2020 Jun;39(6):1958-1967
pubmed: 31522787
Spine (Phila Pa 1976). 2019 Jun 1;44(11):E679-E686
pubmed: 30475342
Patient Prefer Adherence. 2019 Dec 13;13:2089-2100
pubmed: 31997877
Qual Life Res. 2019 Dec;28(12):3163-3175
pubmed: 31201730
Value Health Reg Issues. 2019 May;18:170-175
pubmed: 31096140
Med Care. 2007 Sep;45(9):812-9
pubmed: 17712251
Psychiatry Res. 2019 Apr;274:400-408
pubmed: 30852434
Qual Life Res. 2019 Jan;28(1):121-129
pubmed: 30187395
Arthritis Res Ther. 2019 Jan 30;21(1):41
pubmed: 30700326
J Headache Pain. 2019 May 31;20(1):65
pubmed: 31151382
Eur Urol Oncol. 2019 Sep;2(5):565-571
pubmed: 31412011
Qual Life Res. 2019 Jan;28(1):141-152
pubmed: 30225788
BMJ Open Ophthalmol. 2019 Oct 03;4(1):e000353
pubmed: 31673632
Qual Life Res. 2019 Jul;28(7):1903-1911
pubmed: 30778889
Clinicoecon Outcomes Res. 2019 Sep 03;11:539-550
pubmed: 31564930
Eur Arch Otorhinolaryngol. 2019 Apr;276(4):1039-1047
pubmed: 30607559
BMC Oral Health. 2019 Aug 16;19(1):187
pubmed: 31419988
Epilepsia. 2019 Aug;60(8):1697-1710
pubmed: 31247127
J Bodyw Mov Ther. 2019 Apr;23(2):241-246
pubmed: 31103102
Br J Surg. 2019 Sep;106(10):1311-1318
pubmed: 31216065
Value Health. 2019 Jan;22(1):38-44
pubmed: 30661632
Qual Life Res. 2019 May;28(5):1207-1215
pubmed: 30519906
Value Health. 2019 Jan;22(1):62-68
pubmed: 30661635
Br J Dermatol. 2019 Apr;180(4):802-809
pubmed: 29897626
Value Health. 2019 Nov;22(11):1295-1302
pubmed: 31708067
Eur J Health Econ. 2020 Nov;21(8):1245-1257
pubmed: 32514643
J Med Econ. 2019 Mar;22(3):238-244
pubmed: 30523724
Clin Rehabil. 2019 Jul;33(7):1214-1220
pubmed: 30834774
Medicine (Baltimore). 2019 Mar;98(11):e14895
pubmed: 30882705
Medicina (Kaunas). 2019 Sep 16;55(9):
pubmed: 31527463
Value Health. 2019 Jan;22(1):50-61
pubmed: 30661634
Stroke. 1993 Feb;24(2):320-7
pubmed: 8421836
Appl Health Econ Health Policy. 2017 Apr;15(2):127-137
pubmed: 28194657
J Headache Pain. 2019 Mar 7;20(1):26
pubmed: 30845917
Eur Spine J. 2019 Sep;28(9):2187-2197
pubmed: 31041598
Clin Ther. 2019 Jun;41(6):1066-1079
pubmed: 31101372
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
Pediatr Allergy Immunol. 2019 Aug;30(5):553-561
pubmed: 30968444

Auteurs

Aimin Wang (A)

School of Medical Management, Shandong First Medical University & Shandong Academy of Medical Sciences, Tai'an, China.
Section Medical Psychology and Psychotherapy, Erasmus Medical Center, Rotterdam, The Netherlands.
EuroQol Group Research Foundation, Rotterdam, The Netherlands.

Kim Rand (K)

Health Services Research Center, Akershus University Hospital, Lørenskog, Norway.
Math in Health B.V., Rotterdam, The Netherlands.
EuroQol Group Research Foundation, Rotterdam, The Netherlands.

Zhihao Yang (Z)

Health Services Management Department, Guizhou Medical University, Gui'an, China. zhihao_yang_cn@126.com.
EuroQol Group Research Foundation, Rotterdam, The Netherlands. zhihao_yang_cn@126.com.

Richard Brooks (R)

Health Services Management Department, Guizhou Medical University, Gui'an, China.
EuroQol Group Research Foundation, Rotterdam, The Netherlands.

Jan Busschbach (J)

Section Medical Psychology and Psychotherapy, Erasmus Medical Center, Rotterdam, The Netherlands.
EuroQol Group Research Foundation, Rotterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH